trametinib Articles
Merck & Co prevails in patent fight over Zetia and Vytorin; GSK files for EU approval of melanoma products
8 February 2013
Treatment landscape for thyroid carcinoma will change dramatically through 2021; report
5 February 2013
GlaxoSmithKline initiates Ph III study to test dabrafenib and trametinib combo for BRAF positive melanoma
4 February 2013
Yervoy and Zelboraf accounted for two-thirds of malignant melanoma drug market in 2011; report
18 September 2012
More news from ASCO meeting
5 June 2012
Showing 1-9 of 9 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
